Business Quick Take - Taipei Times
Business Quick Take AstraZeneca upbeat on profit AstraZeneca PLC Thursday forecast revenue growth for this year after the COVID-19 vaccine developer beat analysts’ estimates for fourth-quarter product sales, as a wide range of therapies helped cushion the hit from the pandemic. It expects this year’s revenues to increase by a low teens percentage, with “faster growth” in core earnings to US$4.75 to US$5 per share. Quarterly product sales of US$7.01 billion surpassed a company-compiled consensus of US$6.81 billion. The London-listed company said its forecast did not include any impact ...
Source: taipeitimes.com